HRAS and head and neck squamous cell carcinoma: L. Ho et al., in a single-arm, open-label, phase II trial, demonstrated the encouraging efficacy of tipifarnib, a farnesyltransferase inhibitor that disrupts HRAS function, in patients with R/M HNSCC with mHRAS variant allele frequency (VAF) of ≥20% (high VAF).